Document 0597
 DOCN  M9480597
 TI    Administration of aerosol pentamidine: a program design.
 DT    9410
 AU    O'Hara CM; Anton WR; Gormley FX; Brazell C; HIV/AIDS Programs,
       University of Washington Medical Center,; Seattle.
 SO    J Assoc Nurses AIDS Care. 1994 Mar-Apr;5(2):41-8. Unique Identifier :
       AIDSLINE MED/94305115
 AB    Aerosol pentamidine (AP) is an FDA-approved prophylaxis against
       pneumocystis carinii pneumonia (PCP) in HIV-infected individuals who
       have a CD4+ lymphocyte count less than 200/mm3, constitutional symptoms,
       or a previous history of the pneumonia. The University of Washington
       Medical Center, a 450-bed tertiary care center, established a successful
       aerosol pentamidine treatment program, providing treatment in its
       special procedure nit. The authors present an overview of AP and discuss
       the role of interdisciplinary teamwork, staff training, patient
       teaching, and the provision of safety measures for patients and
       healthcare providers.
 DE    Administration, Inhalation  Aerosols  AIDS-Related Opportunistic
       Infections/*DRUG THERAPY/NURSING  Human  Infection Control  *Patient
       Care Planning  Patient Education  Pentamidine/*THERAPEUTIC USE
       Pneumonia, Pneumocystis carinii/*DRUG THERAPY/NURSING  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).